Clinical trials / NCT06584565
Recruiting

A Multicenter Study Based on Multi-omics Analysis to Predict the Early Prognosis and Recurrence Risk of Acute Ischemic Stroke

Through a multicenter prospective AIS cohort study, we analyze the potential association of human proteome, microbiome and metabolome alterations with AIS prognosis, searching for key proteins, differential organisms and metabolites, combining experimental data at multiple molecular levels with computational models, and establishing early prediction models through machine learning-based prediction algorithms. While closely tracking the recurrence of stroke in AIS patients, we evaluate the predictive value of human…

ClinicalTrials.gov IDNCT06584565
PhaseNot Applicable
Enrollment400
SponsorNanfang Hospital, Southern Medical University
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Ischemic Stroke, Acute

About this study

Through a multicenter prospective AIS cohort study, we analyze the potential association of human proteome, microbiome and metabolome alterations with AIS prognosis, searching for key proteins, differential organisms and metabolites, combining experimental data at multiple molecular levels with computational models, and establishing early prediction models through machine learning-based prediction algorithms. While closely tracking the recurrence of stroke in AIS patients, we evaluate the predictive value of human proteome, microbiome and metabolites for stroke recurrence through a nested case-control study, which provides key reference information for exploring the unknown residual risk of AIS recurrence.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: 1. Meet the diagnostic criteria of AIS according to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 2. Aged 18 to 75 years old 3. Stroke within 7 days of onset 4. Sign informed consent, provide relevant medical history information and provide biological specimens Exclusion Criteria: 1. Severe impairment of consciousness (awareness score of NIHSS\>1) 2. History of stroke within 12 months 3. Severe systemic disease including malignancy 4. ALT or AST\> 2 times the upper limit of normal or severe liver disease 5. creatinine \> 1.5 times the upper limit of normal or severe kidney disease 6. History of long-term drinking, drug use, and chemical poisoning (e.g., pesticide poisoning); Note: Long-term alcohol consumption, usually more than 5 years, over 40 g/day of alcohol for men and 20 g/day for women, or a history of heavy alcohol consumption within 2 weeks, over 80 g/day of alcohol 7. History of intestinal tumors, irritable bowel syndrome or inflammatory bowel disease or confirmed in the hospital 8. Unable to collect a stool specimen within 4 days of admission 9. Assessed to be unsuitable for participation in this study by the investigator

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.